Study to assess safety and tolerability of AZD2171 after multiple doses in patients with advanced prostate cancer - AZD2171IL/0003
Study identifier:D8480C00003
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I open-label dose escalation study to assess the safety and tolerability of AZD2171 following multiple oral doses in subjects with advanced prostate cancer.
Medical condition
Advanced Prostate Adenocarcinoma
Phase
Phase 1
Healthy volunteers
No
Study drug
AZD2171
Sex
Male
Actual Enrollment
40
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Mar 2004
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: Non-randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
Nick Botwood
AstraZeneca
